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Abstract
Sickle cell anaemia (SCA) is a haemoglobin disorder that alters the deformability of erythrocytes through abnormal polymerization of
haemoglobin. Children with SCA have an increased risk of infections with encapsulated bacteria. To guide the antibiotic prophylaxis and
vaccinations in children with SCA in Gabon, we characterized Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus inﬂuenzae
from children with and without SCA. We performed a cross-sectional study and compared nasal and pharyngeal S. pneumoniae,
Staph. aureus and H. inﬂuenzae isolates from SCA children (n = 73) with comparators matched for age, residence and sex (n = 143) in a
matched-comparison analysis. The resistance pattern and capsular type were identiﬁed for each isolate. The total carriage rate for
S. pneumoniae, Staph. aureus and H. inﬂuenzae was 13.8%, 46.7% and 12.5%, respectively, and did not differ between groups (p >0.05).
The mean number of days under antibiotic treatment in the past year was higher in children with SCA than in controls (penicillin: 70.1
vs 0.1 days, p 0.00002). The total non-susceptibility rate was 30% for oral and parenteral (meningitis) penicillin in S. pneumoniae, resis-
tance rates were 1.6% for oxacillin in Staph. aureus and 14.8% for ampicillin in H. inﬂuenzae. Susceptibility to antibiotic agents and distri-
bution of capsular types did not differ signiﬁcantly between both groups. In conclusion, carriage and resistance rates are similar
in children with and without SCA. Our data provide the basis to guide empiric therapy of invasive diseases caused by S. pneumoniae,
Staph. aureus and H. inﬂuenza in children in Gabon.
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Introduction
Sickle cell disease is a monogenic disorder of haemoglobin
and affects 0.74% of all newborns in sub-Saharan Africa each
year [1]. One nucleotide mutation of the b-globulin gene
causes an alteration of the amino acid sequence resulting in
an abnormal polymerization of haemoglobin (Hb) under cer-
tain conditions such as deoxygenation. Heterozygous chil-
dren are asymptomatic carriers of this point mutation and
are protected against malaria [2]. Homozygous carriers
develop sickle cell anaemia (SCA), which is characterized by
the HbSS phenotype. Clinical syndromes associated with
SCA are vaso-occlusive crisis, acute chest syndrome, aplastic
crisis, cerebrovascular accident and haemolytic anaemia [1].
Hypoperfusion of the spleen leads to functional hyposplenism
and may culminate in ‘autosplenectomy’ as the result of
recurrent infarction and haemorrhages [3]. The clearance of
pathogens and the stimulation of the immune system are
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
reduced in hyposplenism or asplenism, so patients with SCA
have a high risk of infections with encapsulated bacteria simi-
lar to the so-called overwhelming post-splenectomy infec-
tions [4,5]. Bacterial infections are most frequently caused by
Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus
inﬂuenzae and non-Typhi Salmonella species [6–8]. Both
immunization against S. pneumoniae and H. inﬂuenzae type b
and antibiotic prophylaxis are recommended to reduce the
risk of fatal infections. However, permanent antibiotic pro-
phylaxis or frequent antibiotic therapies may raise the risk
for the selection of resistant strains and may therefore limit
therapeutic options [4]. As S. pneumoniae, Staph. aureus and
H. inﬂuenzae are part of the nasopharyngeal ﬂora, infections
with these pathogens are mostly endogenous [9,10]. Knowl-
edge of the distribution of capsular types and resistance to
antibiotics is necessary to guide optimal vaccination, antibi-
otic prophylaxis and treatment of these pathogens. As these
data have not been described for Gabon, we collected nasal
and pharyngeal swabs from children with SCA and a matched
healthy group to compare the susceptibility pattern and cap-
sular types of S. pneumoniae, Staph. aureus and H. inﬂuenzae.
Material and Methods
Ethical statement
Ethical approval was obtained from the regional review board
(Comite´ d’E´thique Re´gional Inde´pendant de Lambare´ne´,
Gabon, CERIL09/2010). The participating children and their legal
representatives were informed about the study procedures
and the legal representative or the full-age participant, respec-
tively, gave written informed consent before enrolment.
Population
We performed a cross-sectional study on the carriage of
S. pneumoniae, Staph. aureus and H. inﬂuenzae in children with
and without SCA. Consecutive children with SCA attending
the regular consultations at the Albert Schweitzer Hospital,
Lambare´ne´, Gabon were included in the SCA group if (i)
HbSS had been conﬁrmed by electrophoresis and (ii) they
had not received a blood transfusion in the past 3 months.
Exclusion criteria for both groups were fever and signs of
acute infection. Four children with SCA declined participa-
tion. For each SCA child two controls matched for age
(± 2 years), residence and sex were enrolled, if they were
haemoglobin A (HbA) carriers as conﬁrmed by electrophore-
sis. If controls did not meet all three criteria we gave prior-
ity to age over residence and residence over sex.
Demographic data were recorded for each participant. All
children underwent a physical examination to assess them
for hepatomegaly, splenomegaly and enlarged lymph nodes
by palpation. EDTA-anticoagulated capillary blood was drawn
to test for the presence of HbS and HbA by electrophoresis.
Giemsa-stained thick blood smears were prepared to check
for Plasmodium sp. and ﬁlarial infections.
Haemoglobin electrophoresis
To lyse red blood cells, capillary blood was diluted 1:10 in lysis
buffer (0.2 M Tris–HCl (pH 8.9), 5.1 mM EDTA, 14.6 mM
boric acid, 0.154 M sodium chloride, 4% Ficoll-Plaque, 1%
nonidet P-40) and separated in a 2% agarose gel. The electro-
phoresis was performed in electrophoresis buffer (84.2 mM
Tris–HCl (pH 8.9), 2.05 mM EDTA and 51.8 mM boric acid).
Bacterial culture
Nasal and pharyngeal swabs were stored in Amies transport
medium for a maximum of 3 h until they were subjected to
microbiological culture and identiﬁcation at the medical
research unit in Lambare´ne´, Gabon. Swabs were streaked on
Columbia blood agar plates supplemented with 5% sheep
blood. An aztreonam disc (13 lg; Oxoid, Hants, UK) was
placed on the agar and plates were incubated at 35C for
18–24 h. Swabs were also plated on chocolate agar plates
supplemented with an oleandomycin disc (15 lg; Oxoid) and
incubated at 35C and 5% CO2 for 18–24 h.
Identiﬁcation and susceptibility test
Cultures on Columbia blood agar plates were screened for
two or three presumptive S. pneumoniae colonies, which
were tested for optochin susceptibility. Isolates displaying a
zone of inhibition >14 mm were tested for bile solubility
[11]. Susceptibility was tested applying the broth microdilu-
tion method and breakpoints according to the Clinical Labo-
ratory Standards Institute [12]. For penicillin, we report the
non-susceptibility rates to oral penicillin (MIC >0.06 lg/mL)
and parenteral penicillin (meningitis: MIC >0.06 lg/mL; non-
meningitis: MIC >2 lg/mL).
Presumptive Staph. aureus colonies were identiﬁed by
positive catalase reaction and latex agglutination test (Pasto-
rex Staph-Plus; Bio-Rad Laboratories, Marnes-la-Coquette,
France). Species conﬁrmation and susceptibility tests were
performed using a Vitek 2 automated system (bioMe´rieux,
Marcy l’Etoile, France).
Colonies of Haemophilus sp. were tested for a positive
satellite phenomenon and were subjected to biochemical
identiﬁcation using API NH (bioMe´rieux). As biochemical
identiﬁcation systems do not reliably differentiate between
H. inﬂuenzae and H. haemolyticus, we conﬁrmed the species of
H. inﬂuenzae isolates by 16s RNA gene sequencing [13,14].
Susceptibility was tested using the agar diffusion method [12].
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Capsular typing
Capsular types of S. pneumoniae were identiﬁed using the
Neufeld’s Quellung Reaction and type-speciﬁc antisera (Sta-
tens Serum Institut, Copenhagen, Denmark). Staphylococcus
aureus genes encoding the capsular polysaccharides CP5 and
CP8 were detected by multiplex PCR [15]. The capsule gene
bexA of H. inﬂuenzae and the locus encoding for capsule B
(capB) were detected by PCR [16].
Statistical analyses
The sample size for children with SCA depended on the
number of SCA children attending the follow-up consultation
for SCA. Continuous variables were compared using Stu-
dent’s t-test. To analyse associations between categorical
variables, the OR and the 95% CI were calculated. Statistical
signiﬁcance was tested using either chi-square test or Fish-
er’s exact test. If a participant was colonized with the same
isolate at different body sites as assessed by phenotypic
appearance and capsular typing, we included this isolate only
once in the calculation of resistance rates and prevalence of
capsular types.
Statistical analyses were performed using ‘R’, Version
2.13.1 (http://www.cran.r-project.org) and the package
EPICALC.
Results
Population
From March to June 2010 we enrolled 73 children with SCA
and 143 non-HbSS children matched for age, residence and
sex (Table 1). The majority of the control group had the
HbAA genotype (n = 83, 58.0%), followed by HbAS (n = 56,
39.2%). In four children in the control group, test results for
Hb electrophoresis were inconclusive because it was not
possible to distinguish between HbAA and HbAS. For one
SCA child we were unable to ﬁnd two matched controls and
for two SCA children only one matched control fulﬁlled the
inclusion criteria.
All participants had a negative blood smear for Plasmodium
sp. or ﬁlaria. Nine children of the control group had a miss-
ing healthcare record and were excluded from the analysis
of the exposure to antibiotics. Children with SCA had taken
antibiotics more often during the 12 months before enrol-
ment than children in the control group. For instance, the
mean number of days under penicillin treatment was
70.1 days (SCA children) versus 0.1 days (healthy children,
p 0.00002, Table 1).
Carriage
The total carriage rate for S. pneumoniae, Staph. aureus and
H. inﬂuenzae was 13.8% (n = 30), 46.7% (n = 101) and 12.5%
(n = 27), respectively, and did not differ signiﬁcantly between
groups (p >0.05, Table 2). Children between 1 and 2 years
had the highest proportion of S. pneumoniae carriage (n = 8,
27.3%). The highest Staph. aureus carriage rate was in partici-
pants between 10 and 15 years of age (n = 32, 60.4%). The
H. inﬂuenzae colonization was almost the same in the differ-
ent age groups (11.3–30%).
Susceptibility
The total non-susceptibility rate was 30% for oral and paren-
teral (meningitis) penicillin in S. pneumoniae and was more
frequent in children with SCA than in healthy children, but
TABLE 1. Characteristics of chil-
dren with sickle cell anaemia
(SCA) and their age-, residence-
and sex-matched controls
SCA children
(n = 73)
Healthy
children
(n = 143) OR (95% CI) p-value
Age
Mean age in years (±SD) 7.43 (±4.19) 7.44 (±4.43) NA 0.99
Sex, n (%)
Female 31 (42.5) 68 (47.6) 0.8 (0.4–1.5) 0.48
Residence, n (%)
Lambare´ne´ 52 (71.2) 104 (72.7) 0.9 (0.5–1.8) 0.82
Libreville 3 (4.1) 5 (3.5) 1.2 (0.2–6.3) 1
Ndjole´ 5 (6.9) 10 (7.0) 1 (0.3–3.3) 1
Other 13 (17.8) 24 (16.8) 1.1 (0.5–2.4) 0.85
Physical examination, n (%)
Splenomegaly 22 (30.1) 4 (2.8) 14.6 (4.6–70.0) 0
Hepatomegaly 24 (32.9) 9 (6.3) 7.1 (2.9–18.7) 0
Lymphadenopathy 54 (74.0) 83 (58.0) 2.0 (1.0–3.9) 0.03
Mean number of days under antibiotic treatment in the past year (range)
Penicillina 70.1 (0–240) 0.1 (0–7) NA 0.00002
Ampicillin/amoxicillin 11.6 (0–50) 1.5 (0–21) NA 0.0001
Amoxicillin plus clavulanic
acid/cloxacillin
3.8 (0–29) 0.4 (0–10) NA 0.06
Erythromycin 3.1 (0–51) 0.4 (0–15) NA 0.009
Cotrimoxazole 1.4 (0–24) 0.4 (0–10) NA 0.04
aInlcuding penicillin prophylaxis.
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did not reach statistical signiﬁcance (45.5% versus 21.1%, OR
3, 95% CI 0.5–21.4, p 0.23 for oral and parenteral (meningi-
tis) penicillin).
Non-susceptibility rates of S. pneumoniae to all other anti-
biotics tested were similar in children with SCA and in
healthy children (p >0.05, Table 3). All isolates were suscep-
tible to parenteral penicillin (non-meningitis), parenteral
amoxicillin (non-meningitis), cefotaxim, levoﬂoxacin and
vancomycin.
The total prevalence of methicillin-resistant Staph. aureus
was 1.6% and was similar in children with SCA and in healthy
children (2.2% versus 1.4%, OR 1.6, 95% CI 0.0–125.4, p 1,
Table 3). Resistance rates were not signiﬁcantly higher in
SCA children than in healthy children for macrolides (13.0%
versus 5.6%, OR 2.5, 95% CI 0.6–13.0, p 0.19) and clindamy-
cin (8.7% versus 1.4%, OR 6.7, 95% CI 0.6–337.0, p 0.08,
Table 3). The clindamycin resistance was always inducible. All
Staph. aureus isolates were susceptible to aminoglycosides,
chinolones, glycopeptides and linezolid.
The total resistance rate of H. inﬂuenzae to ampicillin was
14.8% and was lower in SCA children than in healthy chil-
dren, but did not reach statistical signiﬁcance (0% versus
23.5%, OR 0, 95% CI 0–2.5, p 0.26). Lower resistance rates
in children with SCA were also found for tetracycline, co-
trimoxazole and chloramphenicol without reaching statistical
signiﬁcance (p >0.05, Table 3). Resistance to amoxicillin/cla-
vulanic acid, cefuroxime, ceftriaxone, meropenem, levoﬂoxa-
cin and rifampicin was not detected.
Capsular types
The distribution of pneumococcal capsular types did not dif-
fer signiﬁcantly between groups (Fig. 1). However, S. pneumo-
niae serotypes covered by the seven-valent pneumococcal
vaccine were more frequently found in children with SCA
than in healthy children (63.7% versus 36.9%, OR 2.89, 95%
CI 0.5–18.9, p 0.26, Fig. 1). Serotypes 1, 5 and 7F were not
detected, so the coverage rates of the 10-valent and seven-
valent vaccines were identical. The coverage of serotypes
TABLE 2. Carriage rates for Strep-
tococcus pneumoniae, Staphylococ-
cus aureus and Haemophilus
inﬂuenzae in children with and
without sickle cell anaemia (SCA)
Carriage site
SCA children
(n = 73)
Healthy children
(n = 143) Total (n = 216)
S. pneumoniae Nose 5 (6.9) 13 (9.1) 18 (8.3)
Throat 6 (8.2) 4 (2.8) 10 (4.6)
Nose and throat 0 (0) 2 (1.4) 2 (0.9)
Any site 11 (15.1) 19 (13.3) 30 (13.8)
Staph. aureus Nose 17 (23.3) 47 (32.9) 64 (29.6)
Throat 9 (12.3) 13 (9.1) 22 (10.2)
Nose and throat 8 (11.0) 7 (4.9) 15 (6.9)
Any site 34 (46.6) 67 (46.9) 101 (46.7)
H. inﬂuenzae Nose 3 (4.1) 2 (1.4) 5 (2.3)
Throat 7 (9.6) 15 (10.5) 22 (10.2)
Any site 10 (13.7) 17 (11.9) 27 (12.5)
Figures are n (%)
TABLE 3. Non-susceptibility rates of Streptococcus pneumoniae and resistance rates of Staphylococcus aureus and Haemophilus
inﬂuenzae from children with and without sickle cell anaemia (SCA)
Non-susceptibility rate of S. pneumo-
niae Resistance rate of Staph. aureus Resistance rate of H. inﬂuenzae
SCA
children
(n = 11)
Healthy
children
(n = 19)
Total
(n = 30)
SCA
children
(n = 46)
Healthy
children
(n = 72)
Total
(n = 118)
SCA
children
(n = 10)
Healthy
children
(n = 17)
Total
(n = 27)
Penicillin 5 (45.5)a 4 (21.1)a 9 (30)a 46 (100) 70 (97.2) 116 (98.3) NA NA NA
Penicillin, parenteral
(meningitis)
5 (45.5) 4 (21.1) 9 (30) NA NA NA NA NA NA
Penicillin, parenteral
(non-meningitis)
0 (0) 0 (0) 0 (0) NA NA NA NA NA NA
Ampicillin NA NA NA 46 (100) 70 (97.2) 116 (98.3) 0 (0) 4 (23.5) 4 (14.8)
Oxacillin NA NA NA 1 (2.2) 1 (1.4) 2 (1.6) NA NA NA
Clindamycin 1 (9.1) 1 (5.3) 2 (6.7) 4 (8.7) 1 (1.4) 5 (4.2) NA NA NA
Macrolides 1 (9.1) 1 (5.3) 2 (6.7) 6 (13.0) 4 (5.6) 10 (8.5) ND ND ND
Tetracycline 8 (72.7) 14 (73.7) 22 (73.3) 25 (54.3) 36 (50.0) 61 (51.7) 1 (10) 5 (29.4) 6 (22.2)
Cotrimoxazole 8 (72.7) 15 (78.9) 23 (76.7) 21 (45.7) 31 (43.1) 52 (44.1) 6 (60) 15 (88.2) 21 (77.8)
Chloramphenicol 1 (9.1) 0 (0) 1 (3.3) ND ND ND 0 (0) 4 (23.5) 4 (14.8)
Figures are n (%).
NA, not applicable, ND, not done.
p >0.05 for all values.
aNon-susceptibility rates refer to CLSI breakpoints used for oral penicillin therapy of S. pneumoniae.
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included in the 13-valent vaccine was higher in children with
SCA than in healthy participants (72.7% versus 52.6%, OR
2.33, 95% CI 0.4–18.0, p 0.44). The prevalence of vaccine
serotypes included in the 23-valent polysaccharide vaccine
was similar in both groups (63.7% versus 68.5%, OR 0.81,
95% CI 0.1–5.3, p 1).
Children with SCA and healthy children carried Staph. aur-
eus isolates with a similar distribution of CP5 (37% versus
40.3%, OR 0.87, 95% CI 0.4–2.0, p 0.72) and CP8 (63% ver-
sus 59.7%, OR 1.15, 95% CI 0.5–2.7, p 0.72).
One child with SCA carried an H. inﬂuenzae type B isolate
(bexA-positive, capB-positive) and one healthy child a non-B
isolate (bexA-positive, capB-negative).
Discussion
In this study we compared S. pneumoniae, Staph. aureus and
H. inﬂuenzae from children with SCA and healthy compara-
tors matched for age, residence and sex in Gabon. Although
children with SCA took antibiotics more often (Table 1),
the carriage of S. pneumoniae, Staph. aureus and H. inﬂuenzae
was similar in both groups in accordance with another
report [17]. The peak colonization for S. pneumoniae (27.3%
in children between 1 and 2 years) and Staph. aureus (60.4%
in children between 10 and 15 years) was similar to those
reported from industrialized countries [18]. Colonization
with H. inﬂuenzae was lower compared with reports from
Kenya and South Africa (12% versus 20–30%) [19,20].
Recently, a sequence-based study revealed that 27.3% of
nasopharyngeal H. inﬂuenzae isolates, identiﬁed by biochemi-
cal standard methods, were in fact H. haemolyticus [13]. This
could explain the lower carriage rate in our study,
because we conﬁrmed all H. inﬂuenzae by 16S rRNA gene
sequencing and excluded all H. haemolyticus isolates (20%,
n = 7).
Penicillin prophylaxis is recommended for children
under 5 years with SCA, because it reduces the incidence of
pneumococcal infection by 84% [5,21]. There seems to be a
trend to higher non-susceptibility rates of S. pneumoniae
from SCA children to penicillin using the breakpoints for oral
and parenteral (meningitis) therapy (Table 3). However, all
isolates were still susceptible to parenteral penicillin (non-
meningitis breakpoints) in both groups.
Resistance of Staph. aureus to penicillin, tetracycline and
cotrimoxazole was high in both groups, which is consistent
with results from different African countries [22]. The methi-
cillin-resistant Staph. aureus rate in children with SCA and
healthy children (2.2% and 1.4%) was similar to other Gabo-
nese populations (3.7%) [23]. However, clindamycin resis-
tance was more frequent in SCA children and was always
inducible by erythromycin (Table 3). Erythromycin is widely
used for upper respiratory tract infection in Gabon and
could explain the high resistance rates for clindamycin
despite rare prescription of lincosamides. The higher resis-
tance rates of H. inﬂuenzae to ampicillin, tetracycline, cotrim-
oxazole and chloramphenicol in healthy children may be
inaccurate because of the small sample size (Table 3).
Pneumococcal disease is preceded by nasopharyngeal col-
onization with S. pneumoniae and carrier isolates provide
important data on the distribution of capsular types of
S. pneumoniae that eventually cause infection [10]. However,
it is not clear to what extent the serotypes among carrier
isolates can predict the serotypes in invasive isolates [19]. As
S. pneumoniae is easily transmitted between individuals, it
was not surprising that the distribution of capsular types in
both groups was similar (Fig. 1). Differences in the preva-
lence of serotypes were rather the result of the small sample
size. The distribution of capsular types in our Gabonese
study was similar to strain collections from the Netherlands
and Kenya with respect to serotype 6B (10.0 versus 11 and
7.9%) and 23F (10.0 versus 8 and 8.2%). The prevalence of
FIG 1. Distribution of pneumococcal serotypes in children with sickle cell anaemia (SCA) and healthy children. Vaccine serotypes found in this
study were as follows. Seven-valent and 10-valent pneumococcal vaccine: 4, 6B, 14, 19F, 23F. 13-valent pneumococcal vaccine: seven-valent pneu-
mococcal vaccine types plus 6A, 19A. 23-valent pneumococcal vaccine: seven-valent pneumococcal vaccine types plus 11A, 15B, 19A.
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serotype 19F (20.0 versus 11 and 8%) and 6A (3.3 versus 6.7
and 8.6%) differed from results of the Dutch and Kenyan
studies [18,19].
The signiﬁcance of Staph. aureus CP as vaccine candidate
was discussed in the past. A CP5 and CP8 conjugate vaccine
(StaphVAX, Nabi) signiﬁcantly reduced bacteraemia in dialysis
patients during a period of 3–40 weeks after immunization,
but a phase III trial failed to conﬁrm these results [24]. If
CP5 and CP8 were included in polyvalent vaccines, this
would cover 100% of carrier isolates.
Carriage of H. inﬂuenzae type B depends on vaccination
and ranges from 1 to 12%, which is consistent with our
results (3.6% carriage rate) [25].
Our study has several limitations. First, the small sample
size of SCA children and healthy comparators limits the
comparison of both groups in terms of the resistance to
antibiotics and the distribution of capsular surface antigens.
Second, because we only included children with SCA who
were attending the regular consultations, the recruitment
was biased towards children of families with a higher con-
cern for health and maybe higher socio-economic status.
Third, we did not apply the sampling method for nasopha-
ryngeal swabs to assess S. pneumoniae carriage as proposed
by the WHO [11]. Fourth, we did not assess the HIV status,
which interferes with bacterial colonization.
In conclusion, resistance rates of antibiotics used for the
treatment for S. pneumoniae, Staph. aureus and H. inﬂuenzae
infections were similar between Gabonese children with SCA
and healthy Gabonese children. Current recommendations of
penicillin prophylaxis (125 mg penicillin V twice daily) for chil-
dren under 5 years of age with SCA still seem to be justiﬁed
[5,26]. The distributions of vaccine capsular types are similar
to those reported from other African countries and Europe.
Our study lays a basis for larger studies to derive clinical guide-
lines for chemoprophylaxis in children with SCA in Africa.
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